Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Acalabrutinib in Combination With Lisocabtagene Maraleucel in Relapsed/Refractory Aggressive B-cell Lymphomas
Conditions
Interventions
ACALABRUTINIB
LISOCABTAGENE MARALEUCEL
+1 more
Locations
2
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Beth-Israel Deaconess Medical Center
Boston, Massachusetts, United States
Start Date
March 1, 2023
Primary Completion Date
November 23, 2024
Completion Date
March 1, 2029
Last Updated
January 29, 2026
NCT07523555
NCT05272384
NCT06189391
NCT06313957
NCT04447716
NCT02628405
Lead Sponsor
Patrick C. Johnson, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions